Office of Research
Clinical Trials

Leading the Future of Clinical Medicine
The College of Medicine is a hub for groundbreaking clinical research. With over 30 specialized research units, our teams are dedicated to translating laboratory discoveries into life-saving clinical applications. From neurology to oncology, we provide the infrastructure and expertise necessary to push the boundaries of modern medicine.

Browse our Research Units below to view current study listings.

Clinical Trials Search

Amanda Jackson, MD

Amanda Jackson, MD

Gynecologic Cancer

Phase 1

IMGN151 in Gynecologic Cancers

This Phase 1b study tests IMGN151, an investigational cancer drug, in adults with gynecologic cancers. About 377 people will join at about 50 sites. Participants are placed into treatment groups: IMGN151 given with carboplatin, with olaparib, with bevacizumab, or as IMGN151 alone. The main goals are to find dose‑limiting toxicities and to assess safety and side effects over the study period, and to look for early signs that tumors respond (shrink or stop growing). Participants must have good performance status, most need at least one measurable tumor by scan, and must meet timing rules for prior treatments. People with certain ovarian tumor types, prior FRα‑targeting therapy, large prior radiation to the marrow, or other significant medical issues are not allowed. The study lasts about 3 years overall. Participants will come for regular clinic visits for infusions, blood tests, and scans and will stay on treatment until disease progression, unacceptable side effects, or other reasons to stop.

This study may be appropriate for those with: Newly Diagnosed Cancer

Learn More about IMGN151 in Gynecologic Cancers
Thomas Herzog, MD

Thomas Herzog, MD

Gynecologic Cancer

Phase 3

LY4170156 Ovarian- PR or PS

This phase 3 study tests a new drug called LY4170156 in two groups of people with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Part A is for platinum-resistant disease (cancer that returned or grew within 6 months after platinum chemotherapy) and compares LY4170156 to standard chemotherapy or to mirvetuximab. Part B is for platinum-sensitive disease (cancer that returned more than 6 months after platinum) and compares LY4170156 plus bevacizumab to platinum chemotherapy plus bevacizumab. The study looks mainly at how long people live without their cancer getting worse. It also checks overall survival, tumor response, side effects, quality of life, and drug levels in the blood. Eligibility depends on cancer type, prior treatments, and health status. Time in the study varies by how each person responds to treatment.

This study may be appropriate for those with: Metastatic Cancer

Learn More about LY4170156 Ovarian- PR or PS
Bailey Nelson

Bailey Nelson

Gynecologic Cancer | Genitourinary Cancer | Gastrointestinal Cancer

Feasibility of an Oral 5 Strain Probiotic (PGC) for GI Toxicity Mitigation During Pelvic Radiation

The exact mechanism of GI symptoms is elusive, but there is sufficient data to suggest that the intestinal microbiome plays a role in radiation-induced GI injury. This feasibility trial will evaluate whether an oral 5 strain probiotic (PGC) can be safely and effectively administered during pelvic RT. PGC will be supplied by Pendulum Therapeutics. Pendulum has completed trials using PGC in non-cancer conditions. The investigators hypothesize that oral supplementation with PGC for GI toxicity mitigation during pelvic radiation is feasible. The intervention will be considered feasible if probiotic tolerability and patient adherence are appropriate. An overall probiotic adherence rate of ≥ 80% by ≥ 70% of patients will be considered acceptable. If feasible, these results will support evaluation of toxicity mitigation in randomized subsequent Phase II/III trials of PGC supplementation during pelvic radiation.

This study may be appropriate for those with: Metastatic Cancer

Learn More about Feasibility of an Oral 5 Strain Probiotic (PGC) for GI Toxicity Mitigation During Pelvic Radiation